According to a new report by Polaris Market Research, the global cancer biomarkers market was valued at USD 26.48 billion in 2025 and is projected to reach USD 68.84 billion by 2034, expanding at a CAGR of 11.2% from 2026 to 2034. Growth is underpinned by rising global cancer prevalence, expanding biomarker discovery technologies, and accelerating adoption of personalized medicine across key end-use industries.

The best sulforaphane supplement market is gaining attention as consumers increasingly explore nutritional products associated with antioxidant support and healthy lifestyles. Growing awareness of plant-based wellness ingredients and broccoli-derived compounds is supporting product interest. Manufacturers are focusing on formulation quality, bioavailability, and convenient delivery formats. Increasing consumer preference for preventive wellness is also creating opportunities for innovation and market expansion.

What Is Driving Cancer Biomarkers Market Growth?

Demand is climbing as the growing global cancer burden converges with rapid advances in genomic and proteomic discovery platforms. The World Health Organization has identified cancer as the second-leading cause of death worldwide, a trend that continues to push healthcare systems toward earlier detection and more precise treatment selection. Manufacturers and end users are prioritizing personalized medicine, pushing cancer biomarker adoption across diagnostics, drug discovery, and treatment-monitoring workflows. Polaris analysts note that the convergence of artificial intelligence and liquid biopsy innovation is positioning the market for sustained double-digit growth through 2034, with diagnostics emerging as the largest revenue contributor and personalized medicine posting the fastest incremental gains.

Key Trends Shaping the Cancer Biomarkers Industry

AI-Enabled Biomarker Discovery

Artificial intelligence and machine learning are accelerating biomarker discovery by identifying complex patterns in genomic and protein data far faster than conventional methods, supporting more effective and individualized treatment planning.

Rise of Liquid Biopsy and Non-Invasive Testing

Non-invasive liquid biopsy tests are gaining ground for real-time, ongoing monitoring of cancer progression and treatment response, extending biomarker use well beyond traditional tissue analysis while depending on strong clinical validation and regulatory clearance to scale.

Companion Diagnostics and Precision Oncology Investment

Growth in companion diagnostics is helping pharmaceutical and diagnostics companies pair biomarkers with targeted therapies, while continued R&D investment, strategic partnerships, and acquisitions among industry players are reshaping the competitive landscape and expanding the market outlook.

Market Segmentation: Breaking Down the Cancer Biomarkers Market

Polaris segments the cancer biomarkers market by cancer type, biomolecule, application, and profiling technology, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Cancer Type

The market spans breast, prostate, colorectal, cervical, liver, and lung cancer, among others. The lung cancer segment is expanding at the fastest pace, driven by rising lung cancer incidence linked to smoking and environmental pollution, along with growing use of non-invasive liquid biopsy and circulating tumor DNA testing for earlier detection and management.

By Biomolecule

Genetic biomarkers account for the largest share of the market, reflecting their central role in detecting cancer-related mutations, guiding targeted-therapy decisions, and supporting companion diagnostics enabled by next-generation sequencing. Proteomic biomarkers are the fastest-growing biomolecule segment, fueled by increasing use of protein expression profiling and mass spectrometry to understand cancer progression, treatment resistance, and pathway activity that genomics alone does not explain.

By Application

Diagnostics is the leading application segment, reflecting rising demand for accurate, biomarker-driven cancer screening as incidence rates climb and technologies such as liquid biopsy mature. Personalized medicine is the fastest-growing application, as biomarkers increasingly help clinicians match patients to genetic or molecular profiles suited to individualized treatment approaches.

By Profiling Technology

On a profiling-technology basis, the market is studied across imaging technology and OMICS-based platforms, with OMICS approaches — spanning genomics, proteomics, and related multi-omics techniques — playing a growing role as discovery pipelines shift toward more comprehensive molecular characterization of tumors.

 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/cancer-biomarkers-market 

Regional Outlook: Where Is the Cancer Biomarkers Market Growing Fastest?

North America led the cancer biomarkers market in 2025 on the strength of advanced healthcare infrastructure, substantial cancer-research investment, favorable regulatory support, and a dense concentration of pharmaceutical, biotechnology, and diagnostics companies, with the United States as the region's largest single market. Asia Pacific is expected to post the fastest CAGR through 2034, driven by rising cancer incidence, expanding healthcare infrastructure, and growing government support in countries such as China, India, and Japan. Europe rounds out the leading regions, supported by well-established healthcare systems, precision-oncology initiatives, and cross-border research collaboration, with Germany, the UK, and France as the region's top contributors.

Competitive Landscape: Leading Cancer Biomarkers Companies

Key players profiled in the report include Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Qiagen N.V., Illumina, Inc., and Bio-Rad Laboratories, alongside Agilent Technologies, PerkinElmer, Inc., Hologic, Inc., Myriad Genetics, Inc., Exact Sciences Corporation, Siemens Healthineers, Genomic Health, Inc., Becton, Dickinson and Company, Biocartis, Foundation Medicine, Inc., and Guardant Health, Inc. These companies are focusing on R&D investment, new-assay launches, NGS platform expansion, and strategic partnerships to strengthen their position across the diagnostics and personalized-medicine segments outlined above. Recent moves include Roche's November 2024 launch of a new genomic profiling test aimed at identifying cancer-related genetic mutations to advance personalized treatment, and Thermo Fisher Scientific's expanded collaboration that same month with oncology research company Mainz Biomed to develop and commercialize colorectal cancer screening products.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the cancer biomarkers market, this report benchmarks market share, segment-level trends, and forecast data — by cancer type, biomolecule, application, profiling technology, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking liquid biopsy and companion diagnostics as growth adjacencies.

More Trending Latest Reports By Polaris Market Research:

cloud-computing-market

us-geothermal-energy-market

essential-oil-market

electric-vehicle-battery-market

abrasives-market

sodium-ion-battery-market

digital-signature-market

outdoor-living-structures-market

base-oil-market